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Airway disease in cystic fibrosis (CF) is characterised by a continuous cycle of chronic infection and inflammation dominated by a
neutrophilic infiltrate. This inflammation is characterised by an increased production of pro-inflammatory cytokines in the lung. The
relationship between the abnormal CFTR gene product and the development of inflammation and progression of lung disease in CF is not
fully understood. This review article studied the mechanisms of pulmonary inflammation in CF, the profiles of cytokines and inflammatory
mediators in the lung in CF, the mechanisms that predispose to chronic Pseudomonas aeruginosa infection, cytokine involvement in diseases
other than CF and reviewed current therapeutic strategies for CF. Imbalances of cytokine secretion are now better understood due to recent
advances in understanding CF at a molecular level and it is increasingly thought that the normal inflammatory process is deranged in CF early
in the course of the disease and may occur in the absence of detectable infection. However, the relationship between this unbalanced cytokine
production, the mutations in CFTR and its actual consequence for pathogenesis need further investigation.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Airway disease in cystic fibrosis (CF) is characterised by
chronic infection and an inflammatory response dominated
by a neutrophilic infiltrate (Fig. 1). There is incomplete
understanding of the relationship between the abnormal3 (2004) 223–231ed by Elsevier B.V. All rights reserved.





Increases adhesion of neutrophils to endothelium
IL-8 Increases chemotaxis of neutrophils to site of inflammation
Activates neutrophils
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and progression of lung disease in CF [1].
Evidence suggests that airway inflammation in CF is
associated with increased production of pro-inflammatory
cytokines in the lung. Airway epithelial cells, macrophages,
and neutrophils are all capable of producing cytokines.
Several studies have found elevated concentrations of pro-
inflammatory cytokines such as interleukin-1 (IL-1), IL-6,
IL-8, and tumour necrosis factor-alpha (TNFa) in the
sputum and bronchoalveolar lavage fluid (BALF) of
patients with CF [1]. Their synthesis is promoted by the
transcription factor nuclear factor-nB (NF-nB), which plays
an important role in intracellular signalling for the produc-
tion of pro-inflammatory cytokines [2]. IL-10, IL-1 receptor
antagonist protein (IRAP), and soluble TNFa receptor
(TNFsR) are anti-inflammatory cytokines that are relatively
down-regulated in CF airway cells [3]. The principle action
of IL-10 is to increase the synthesis of I-nB, the inhibitor of
NF-nB. Downregulation of IL-10 leads to increased pro-
inflammatory cytokines due to less inhibition of NF-nB
actions [2]. Table 1 lists the actions of both the pro-
inflammatory and anti-inflammatory cytokines. The aim of
this review is to give an overview of the role of cytokines
and their dysregulation in the pathogenesis of lung disease
in CF, and to discuss current and future anti-inflammatory
treatments in CF.Increases expression of adhesion molecules
TNFa Increases chemotaxis of neutrophils to site of inflammation
Increases adhesion of neutrophils to endothelium
Induces synthesis of chemoattractant neutrophils
Increases intermediary metabolism
IL-6 Mediates acute-phase reaction
Matures B-lymphocytes
Activates T-lymphocytes
IL-10 Inhibits secretion of TNFa and other cytokines
Inhibits antigen presentation
IRAP Inhibits IL-1 receptor binding
Antagonises activities of IL-1
IL-1, interleukin-1; IL-8, interleukin-8; TNFa, tumour necrosis factor-
alpha; IL-6, interleukin-6; IL-10, interleukin-10; IRAP, interleukin-1
receptor antagonist protein.2. Injury and remodelling
The most characteristic feature of inflammation in the CF
lung is neutrophil infiltration into the airways. The
excessive release of oxidants and proteases, including
neutrophil elastase by infiltrating neutrophils, plays an
important role in tissue damage [4]. This results in
disruption of the elastin fibres and other matrix proteins,
and increased degradation in infected patients [4,5]. Anti-
protease defenses of the CF lung are overwhelmed by a
combination of endogenous and bacterial proteases ratherthan a primary abnormality in the production of protease
inhibitors [4], so there is uninhibited proteolytic enzyme
activity. Elastase directly damages the airway wall by
digesting elastin and other structural proteins; it increases
mucus secretion, cleaves vital opsonins and receptors
necessary for phagocytosis, and promotes the generation
of chemoattractants, thus fueling the vicious cycle of
infection and inflammation that leads to lung destruction
[6]. Other serine proteases such as the cathepsins may also
be important in the process of lung injury.
Matrix metalloproteinases (MMPs), a group of calcium-
and zinc-dependent endopeptidases involved in tissue
breakdown and repair, cell migration, and turnover of
extracellular matrix (ECM) components [7,8], are also
thought to be important in the normal remodelling process
[9] and in the increased ECM destruction seen in many
diseases [10,11]. More than 20 MMPs have now been
described, which are inactivated by specific tissue inhib-
itors (TIMPs) [12]. MMP-8 and MMP-9 are the most
important in the CF airways as they are mainly derived
from neutrophils in the lower respiratory tract [13]. A
recent study by Ratjen et al. [13] demonstrated that MMP-8
and MMP-9 are increased in the BALF of CF patients with
mild lung disease, with a rise in TIMP not in proportion to
the elevated MMPs. Although the role of MMPs in CF lung
disease is not clearly understood, it is thought that excess
MMPs play a role in the continuing cycle of inflammation
and injury.
Lung injury also results in the synthesis of transforming
growth factor-alpha (TGFa) [14]. TGFa is thought to play
a role in the regulation of remodelling following injury in
the lungs of individuals with CF as its expression is
increased in CF lung tissues compared to those without CF
[14]. Remodelling of the airways in vitro has been found to
be associated with the continual presence and release of
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13) during cycles of epithelial injury and repair [15].3. Inflammation before infection?
Excessive inflammation in the airways may be due to
the persistence of stimuli for cytokine production, such as
bacteria, or a constitutive abnormality in the regulation of
cytokine production by cells, or both. Airway inflamma-
tion in CF patients is often viewed as a response to
infection, but studies have shown that inflammation and
infection are early events in CF lung disease in infants
without clinically apparent lung disease [16]. There is
uncertainty regarding what actually initiates the cycle of
persistent inflammation and infection leading to lung
injury and destruction.
Several studies of BALF from infants with CF have
documented the presence of increased inflammatory
markers often in the absence of CF-related pathogens
[17–19]. Two studies have shown that some infants with
CF had airway inflammation in the apparent absence of
infection, although in the study by Khan et al. [17] and
Armstrong et al. [20], the patients had respiratory symp-
toms. However, in the infants, the degree of inflammation
was less when compared to the BALF of CF infants in
whom microorganisms were isolated. In one of these
studies, aspiration lung disease was felt to be responsible
for inflammation in the absence of infection in two infants.
One possible conclusion is that inflammation precedes
infection by some direct contribution of the defective CFTR
[6]. An alternative explanation is that bacteria that are
below detectable levels are generating an inflammatory
response. It is also possible that the inflammatory response
and/or treatment effectively cleared the infection, but the
inflammation then persisted in the absence of bacterial or
viral stimuli [6]. A further hypothesis is that endogenous
signals may be generated, leading to an intense inflamma-
tory response with the production of factors that could
damage the airway surface, and so favour infection and
bacterial colonisation [21].
Airway epithelial cells with abnormal CFTR have a
lower threshold for bacterial adhesion and an augmented
cytokine production response to adherent bacteria [22–
24]. In vitro data have shown that lung epithelial cells
that express defective CFTR have elevated production of
pro-inflammatory cytokines and increased activation of
NF-nB [25–27]. CF mononuclear cells have also demon-
strated selective cytokine dysregulation after maximal
activation. Moss et al. showed a reduced interferon-
gamma (IFN-g) secretion and increased IL-10 mRNA
without increased production or secretion, suggesting that
the cytokine imbalance already described in epithelial
cells also occurs in immunoregulatory cells, further
suggesting a link between CFTR mutations and cytokine
dysregulation [28].4. Cytokine profile
The inflammatory response in the CF lung is the result
of a complex balance between pro-inflammatory and anti-
inflammatory mediators. CF cell lines produce more pro-
inflammatory cytokines than normal cell lines in response
to Pseudomonas aeruginosa infection [29] and it has been
shown that they are elevated in the epithelial lining fluid
(ELF) of CF patients compared to healthy controls [30].
Not only is there increased neutrophil infiltration into CF
airways—these neutrophils probably differ from normal
neutrophils in that they have an increased propensity to
release their granule proteins when stimulated, which may
be as a direct result of CFTR mutation [31,32].
The ELF of CF patients compared to healthy controls
has reduced levels of anti-inflammatory cytokine IL-10 [3],
which inhibits the production of TNFa, IL-1h, IL-6, and
IL-8 by macrophages [33,34]. Two other anti-inflammatory
cytokines are IRAP and TNFsR. IRAP is produced by
macrophages in response to an inflammatory stimulus [35]
and is a specific antagonist to IL-1a and IL-1h. Two types
of receptors exist for TNFa: those attached to the cell
membrane and those soluble in extracellular fluid, both of
which act as natural antagonists competing for TNFa
binding. Bonfield et al. [30] showed that IRAP and TNFsR
were increased in the ELF of CF patients compared to
controls. This rise was proportionately less than that of the
pro-inflammatory cytokines, resulting in a relative defi-
ciency of these natural antagonists [30]. The abnormal
regulation of cytokine release from CF epithelial cells may
be due to CFTR dysfunction, but as yet the link is unclear
[6]. Thus, if there is a reduction in the levels of anti-
inflammatory cytokines (actual or relative) as well as
increased production of pro-inflammatory cytokines, exces-
sive and persistent inflammation will be the result.
Most of the tissue damage in CF is due to activated
neutrophils despite the chronic ongoing nature of the
inflammation [36], indicating a predominant humoral
response and weak cellular response to infection [37,38].
Since the demonstration that the mouse T helper (Th) cell
clones into either Th1 (IFN-g-producing) or Th2 (IL-4-, IL-
5-, or IL-10-producing) cells, the outcome of chronic
infections has been thought to depend on the differences in
the specific Th cell response [39,40]. Animal studies have
demonstrated that in chronic P. aeruginosa lung infection
in mice with a pulmonary Th1 response, there was lower
mortality, faster clearance of bacteria, and milder lung
inflammation in comparison to mice reacting with a Th2
response [41,42]. In CF patients with chronic infection,
those with the highest IFN-g production had the best lung
function [43]. Peripheral blood mononuclear cells from
these patients stimulated with P. aeruginosa antigen
demonstrated a Th2-dominating response in CF patients
with stable chronic P. aeruginosa lung infection as
compared to CF patients without chronic P. aeruginosa
lung infection [43]. A high RNA expression of IFN-g and
Table 2
Cellular source of cytokines produced in human airways
Neutrophils Epithelial cells Macrophages Lymphocytes
IL-1h + + +++
IL-6 + + +++ +
IL-8 +++ ++ ++ +
IL-10 ++ + ++
TNFa ++ + +++ +
IRAP + +++
TNFsR ++ + +
IL-1h, interleukin-1beta; IL-6, interleukin-6; IL-8, interleukin-8; IL-10,
interleukin-10; TNFa, tumour necrosis factor-alpha; IRAP, interleukin-1
receptor antagonist protein; TNFsR, tumour necrosis factor soluble
receptor.
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biopsies was associated with milder disease in CF patients
[44]. The predominance of a Th1 or Th2 response is thought
to depend on the type of dendritic cell that is responsible for
the priming of the T cells to new antigens [45,46]. This
process is in turn thought to be determined by the
granulocyte–macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-CSF)
balance in CF [45]. The skewed T-helper response in CF in
favour of Th2 may be an important factor in the outcome of
infection with microorganisms.
Some studies have found that blood levels of pro-
inflammatory cytokines are undetectable, in contrast to the
greatly elevated concentrations in the sputum and BALF of
CF patients indicating a florid inflammatory response that is
compartmentalised to the local environment of the lungs
[47]. Salva et al. [48] made reference to several studies that
documented elevated concentrations of inflammatory medi-
ators such as IL-1, IL-6, IL-8, and TNFa when not only
sputum or BALF but also serum of patients with CF were
compared with normal controls. In CF patients with chronic
P. aeruginosa infection studied for 6 months prior to death,
there were increased circulating levels of C-reactive protein
(CRP), TNFa, and elastase complex (an inflammatory
marker that reflects neutrophil activity) [49]. This suggests
that the increased inflammatory activity present in the CF
lung is reflected in the systemic circulation.
The inflammatory response also has systemic effects
contributing to other features of CF such as cachexia,
hyperglobulinaemia, and osteopenia [35,50–53]. TNFa in
the systemic circulation alters intermediary metabolism,
increasing resting energy expenditure (REE), stimulating
lipolysis and catabolism, and causing anorexia and weight
loss [54,55]. Clinically stable CF patients who are chroni-
cally infected with P. aeruginosa have elevated circulating
levels of TNFa compared to healthy controls [56]. The
levels of TNFa are increased further during an acute
pulmonary exacerbation. Patients with CF have an increased
REE and tend to be underweight [57]. An association
between raised circulating levels of TNFa and measures of
body wasting and intermediary metabolism (REE) has been
demonstrated [58]. Bell et al. [59] showed that there was a
relationship between raised REE, inflammatory markers,
and catabolic status in patients with chronic P. aeruginosa
infection at the start of an acute pulmonary exacerbation.
These factors showed a subsequent parallel reduction
following intravenous antibiotics, which is further evidence
suggesting a link between cytokines and intermediary
metabolism in patients with CF.
Aris et al. [60] showed an important link between
pulmonary infection and inflammation in CF and unfav-
ourable alterations in bone metabolism. These data sup-
ported the possibility that lung-derived inflammatory
cytokines promote bone resorption and diminished bone
formation, but did not demonstrate an actual loss in bone
mass. Many CF patients suffer from low bone mineraldensity from osteoporosis or osteomalacia, fractures, and
kyphosis [61,62]. The pathogenesis of bone disease in CF is
not well understood [63], but it is undoubtedly multi-
factorial. Studies have shown that pro-inflammatory cyto-
kines, especially TNFa and IL-1h, are important promoters
of bone resorption and inhibit bone formation [60,64,65].
Further studies will be needed to determine which factors
are most important in the bone disease that occurs in CF and
the role played by cytokines.
Airway epithelial cells may be involved directly in the
excess inflammation by several mechanisms. Pro-inflam-
matory cytokines arise from airway epithelial cells, as well
as from macrophages and infiltrating neutrophils (Table
2). Airway epithelial cells also express large numbers of
the important pro-inflammatory adhesion molecule,
ICAM-1. This adhesion molecule is a ligand for neutro-
phils, and adhesion is thought to result in increased IL-8
production, leading to persistence of neutrophils in the
airway [6]. P. aeruginosa pili bind to airway epithelial
cells using the asialo-GM 1 receptors. It has been
suggested that a CF mutation-related sialyation defect
may be the cause of increased numbers of these receptors
on CF cells [66,67]. The fact that epithelial cells
themselves are involved in cytokine release and are
thought to play a major role in the local inflammation
leads to further speculation that defective CFTR function
(expressed most importantly in the epithelial cells) may be
directly related to excessive inflammation.
Airway surface epithelial cells may also contribute to
the pro-inflammatory status of the airway by altering the
composition of airway surface fluid (ASF). Salt-sensitive
antibacterial peptides may be rendered inactive by the
NaCl concentration in ASF, changing from normally
hypotonic (85 mM) to hypertonic (N115 mM), which
has been suggested as a result of defective CFTR
function [68,69]. Tabary et al. [70] showed that CF
human bronchial gland cells (HBGs) had increased IL-8
production even in hypotonic NaCl concentration when
compared to non-CF HBG cells, and that this IL-8
production was further increased with isotonic and
hypertonic NaCl.
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Despite its multiorgan involvement, the progression of
pulmonary disease decides the clinical outcome in the
majority of patients. P. aeruginosa is the most important
pathogen in CF. In spite of a high antibody response to P.
aeruginosa both in the lungs and in the circulation, the
bacteria are not eradicated after the infection is established,
leading to chronic infection with destruction of the airways
and lung function decline. Several hypotheses exist to
explain the high prevalence and chronic nature of P.
aeruginosa infection in CF. Some studies have suggested
that the abnormal CFTR results in increased P. aeruginosa
adhesion to airway epithelial cells [21–24], which in turn
results in an augmented cytokine response, specifically IL-8
production [66]. The absence of CFTR at the apical surface
of the epithelial cells is thought to result in impaired
internalisation and killing of P. aeruginosa [71].
Another hypothesis suggests a reduced activity of beta-
defensin-1 peptides due to a high concentration of NaCl in
CF ASF [72–74]. But in vitro and in vivo data have
demonstrated that ASL is isotonic, thus making this
mechanism less likely [75–77].
In vitro studies by Worlitzsch et al. [78] demonstrated that
the periciliary liquid layer is volume-depleted, resulting in
reduced mucus clearance, which, along with raised oxygen
consumption by CF epithelia, leads to thick hypoxic mucus.
P. aeruginosa then penetrates and grows in the hypoxic zones
and proliferates to form biofilm-like macrocolonies, making
the infection more resistant to defense mechanisms.
Whatever the actual features of the host–bacterial
relationship that lead to the establishment of the chronic P.
aeruginosa infection in CF, it seems clear that this is a
critical event in beginning the inflammatory process that is
eventually responsible for most of the morbidity and
mortality in CF.6. Cytokines and clinical disease
Although it has been shown that concentrations of
inflammatory mediators are markedly elevated in the
sputum or BALF of CF patients when compared with
control subjects, few studies find a correlation between
cytokine concentrations and clinical status.
Induced sputum is increasingly being used as a research
tool as it is a safe, reproducible method of studying the
airways of patients with respiratory disease [79]. The
inflammatory cell population and microbiology in induced
sputum are representative of CF airways [80]. Bronchoal-
veolar lavage (BAL) is a reproducible, well-validated
method used for the study of markers of inflammation and
inflammatory cells in numerous lung diseases including CF
[81,82]; however, it is more invasive than sputum induction.
Wolter et al. [47] and Salva et al. [48] were unable to
find a correlation between levels of inflammatory media-tors in sputum and clinical parameters during periods of
well-being and during acute respiratory exacerbations,
indicating that these markers are unreliable as predictors
of disease status. A possible explanation that may be used
to account for this lack of correlation is that the presence of
acute-on-chronic inflammation may not allow for further
augmentation in IL-8 or other cytokine production [48].
Alternatively, the ability of older patients to produce IL-8
may be reduced [49]. Some cross-sectional studies,
however, have found a correlation between cytokine levels
and clinical status [20,83]. IL-6 has been shown to be a
potent inducer of the acute phase response and CRP is a
surrogate marker for IL-6. Inflammatory markers such as
CRP, TNFa, and elastase complex have been found to be
elevated during symptomatic deterioration and subse-
quently have decreased during appropriate antibiotic
therapy [49]. This may have clinical relevance, but the
benefits of monitoring cytokines in the clinical setting have
yet to be demonstrated.7. Other diseases
Cytokines are known to be involved in regulating normal
physiological processes, but excess or decreased cytokine
production is associated with disease [84,85]. Altered
cytokine profiles are thought to play a major role in various
diseases such as sepsis, ARDS, rheumatoid arthritis (RA), and
inflammatory bowel disease. For example, in RA, mono-
nuclear cells, synovial fibroblasts, chondrocytes, and osteo-
clasts are stimulated to release cytokines especially TNFa, IL-
1, and IL-6, which in turn result in synovial inflammation and
the clinical features associated with RA [86].
Therapy directed at cytokine response has obvious
potential to modify disease, yet significant impact on clinical
status has yet to be proven. Anti-TNF therapies have been
approved for RA and inflammatory bowel disease, and
although they do provide symptomatic relief, the long-term
effects of these treatments are as yet unknown [84].8. Anti-inflammatory therapy
Inflammation is a vital process needed to counteract
infection, but it is increasingly thought that the normal
inflammatory process is deranged in CF early in the course of
the disease [6,87]. The aim of anti-inflammatory therapy
therefore is to gain the balance between dusefulT and
dinappropriateT inflammation [66]. Several approaches to
anti-inflammatory treatment in CF have been studied in the
last few years, including oral and inhaled corticosteroids
(ICS), nonsteroidal anti-inflammatory drugs (NSAIDs), and,
more recently, macrolide antibiotics and a range of antiox-
idants and antiproteases. Long-term oral corticosteroids have
been shown to lower immunoglobulin G (IgG) levels and
cytokine concentrations in CF patients [88], but the signifi-
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centre trial by Eigen and Rosenstein [89] demonstrated an
improvement in lung function in patients with mild to
moderate lung disease treated with alternate day prednisolone
for a period of up to 24 months. An increase in adverse events
was noted if treatment extended beyond 24 months. Ques-
tions still remain, however, as to the timing of steroid use in
relation to the age of the patient and the severity of lung
function [89]. At the present time, there is no place for the
routine long-term use of oral corticosteroids. ICS seem a
reasonable treatment due to their anti-inflammatory proper-
ties but with limited systemic absorption. However, there is
limited conclusive data in support of the efficacy of ICS in
CF. There is a need for larger multicentre clinical trials to
examine efficacy and safety [90,91].
The good safety profile and potent anti-inflammatory
action of NSAIDs have resulted in clinical trials to assess
their potential role in CF. High-dose ibuprofen has been
shown to inhibit neutrophil recruitment to mucosal sites in
vivo [92]. It has been demonstrated that patients treated with
high-dose ibuprofen had a slower rate of FEV1 decline, better
maintained weight, and chest X-ray scores with no significant
adverse events in comparison with placebo [93]. Despite this,
the use of high-dose ibuprofen as an anti-inflammatory agent
in CF remains quite low due to its complex pharmacokinetics,
fears of adverse events, and lack of multicentre trials [90].
There is increasing interest in macrolide antibiotics
following their possible anti-inflammatory effects seen in
Japanese panbronchiolitis [94]. Their mechanism of action is
still unclear but may be due to an anti-inflammatory action of
decreasing production of pro-inflammatory mediators or due
to antimicrobial activity especially against P. aeruginosa
[95]. In a 3-month study, adult CF patients treated with
azithromycin demonstrated maintenance of lung function,
fewer courses of intravenous antibiotics, improved quality of
life, and a decrease in CRP compared to placebo [96]. Equi et
al. [97] studied the effects of long-term azithromycin in
children with CF and found a significant beneficial group
response in lung function. Neither study revealed any
significant adverse event associated with treatment. A large
multicentre placebo-controlled, double-blinded trial of azi-
thromycin in adult patients with CF who were chronically
infected with P. aeruginosa showed a sustained beneficial
treatment effect in lung function, detectable after 28 days of
treatment. Azithromycin was well tolerated in this study in
which there was also a reduction in the number of
exacerbations and an improvement in body mass index [98].
The relative lack of antiproteases in the CF airway has
led to trials investigating the anti-inflammatory properties of
exogenous a1 antitrypsin (the major antiprotease in the
lung). Initial clinical studies with serum-derived, aerosolized
a1 antitrypsin have shown a reduction in neutrophil elastase
activity [99,100]; however, a large multicentre trial did not
demonstrate any beneficial effects [101].
Ramdin et al. [102] suggested that heparin had immuno-
modulatory effects in vivo by demonstrating the binding andinhibition of IL-8. However, due to the complex genetics of
heparin clearance, therapeutically, it is difficult to assess the
dose of heparin required to modify cytokine activity. Further
clinical trials are required to assess the potential for heparin as
an anti-inflammatory agent in CF [102].
The complexity of the inflammatory process in the CF
airways has led to interest in other possible anti-inflammatory
agents including antioxidants, leukotriene receptor antago-
nists, and anti-TNFa therapies that need further evaluation as
potential therapeutic agents in CF [90].9. Conclusion
The balance of pro-inflammatory and anti-inflammatory
mediators and the recruitment of neutrophils by chemo-
attractant cytokines are very important in the pathophysiol-
ogy of CF. Imbalances of cytokine secretion are now better
understood due to recent advances in understanding CF at a
molecular level. However, the relationship between this
unbalanced cytokine production, the mutations in CFTR, and
its actual consequence for pathogenesis needs further
investigation. The bacteria–host immune response interac-
tion comprises a vicious cycle of chronic infection and
inflammation. Antibiotic therapy alone addresses only the
microbiological component of the interaction and, at present,
there is increasing interest in the adjunctive use of anti-
inflammatory agents. Oral corticosteroids have significant
anti-inflammatory actions, but adverse effects with long-term
treatment limit their use. More recently, work has focused on
less toxic oral agents and inhaled anti-inflammatory therapies
such as ICS; however, studies demonstrating their value so
far have not been conclusive. Increased knowledge and
understanding of the mechanisms involved in lung injury
should result in advances in immunomodulatory therapies
that might lead to major contributions to the treatment of the
disease in the future [47,96].Acknowledgement
Grant Support-Research and Development Project Grant,
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